ReviewCurrent urology reports2025
Multiomics in Renal Cell Carcinoma: Current Landscape and Future Directions for Precision Medicine.
Review in Current urology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut microbiome impact on systemic therapy outcomes in metastatic renal cell carcinoma: a systematic review.World journal of urology · 2026Pooled it
- Article
- Robot-assisted vs open partial nephrectomy: a propensity-matched analysis of perioperative outcomes and midterm oncologic safety.International urology and nephrology · 2026Article
- LCAT exhibits subtype specific prognostic and immunometabolic associations in renal cell carcinoma.Discover oncology · 2026Article
- From Genes to Proteins: The Indispensable Role of Proteogenomics in Advancing Clear Cell Renal Cell Carcinoma Research.International journal of molecular sciences · 2026Review
- Insights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective.International journal of surgery (London, England) · 2026Article
- ACACA modulates R-loop homeostasis to enhance lipid metabolism and microenvironmental interactions in ccRCC.NPJ precision oncology · 2026Article
- UBE2S emerges as a key driver in an NK cell-based prognostic model for clear cell renal cell carcinoma.PloS one · 2026Article
- Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review).Frontiers in oncology · 2026Review
- Multi-omics insights into tumor grade progression in clear cell renal cell carcinoma: from molecular mechanisms to precision therapeutics.Frontiers in cell and developmental biology · 2026Review
- Integrative multi-omics profiling for early diagnosis, stratification and personalized management of chronic kidney disease: a new paradigm.Clinical and experimental medicine · 2025Review
- Emerging technologies and clinical translation of urine-based liquid biopsy in urological cancers.Genes & genomics · 2025Review
- Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients.Journal of translational medicine · 2025Review
- Gastric metastasis of renal cell carcinoma: features, mechanisms, and insights from existing literature.Frontiers in cell and developmental biology · 2025Review
- Metabolic reprogramming in clear cell renal cell carcinoma: core pathways and targeted therapeutic strategies.Frontiers in genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewRenal cell carcinoma (RCC) is a prevalent and increasingly diagnosed malignancy associated with high mortality and recurrence rates. Traditional diagnostic and therapeutic approaches have limitations due to the disease's molecular heterogeneity. This review aims to explore how the integration of omics sciences-genomics, transcriptomics, proteomics, and metabolomics-can enhance the diagnosis, prognosis, and treatment of RCC. RECENT
findingsGenomic analyses have uncovered critical mutations, including VHL, PBRM1, and BAP1, which support improved risk stratification and the development of targeted therapies. Transcriptomic and spatial transcriptomic studies have provided deeper insights into RCC heterogeneity and tumor microenvironment dynamics. Proteomic investigations have revealed potential biomarkers, while metabolomic approaches have highlighted RCC-specific metabolic shifts. Despite these advancements, several challenges persist, including intratumoral heterogeneity, difficulties in multi-omics data integration, and the limited clinical validation of biomarkers. Omics-driven approaches hold significant promise for advancing precision medicine in RCC. These technologies can facilitate earlier diagnosis, guide individualized therapies, and enhance prognostic evaluations. Future research must focus on validating multi-omic biomarkers and leveraging artificial intelligence to manage complex datasets, thereby supporting more informed clinical decision-making and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.